Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;81(9):816-824.
doi: 10.1055/s-0043-1772832. Epub 2023 Oct 4.

Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation

Affiliations

Brazilian version of the CHOP INTEND scale: cross-cultural adaptation and validation

Renalli Manuella Rodrigues Alves et al. Arq Neuropsiquiatr. 2023 Sep.

Abstract

Background: Spinal muscular atrophy (SMA) is a rare genetic disease that causes progressive muscle weakness and impacts motor function. The type I is the most severe presentation and affects infants before 6 months old. In addition, the instruments available for assessing motor function have limitations when applied to infants with neuromuscular diseases and significant muscle weakness.

Objective: To translate, cross-culturally adapt, and validate the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) to Brazilian Portuguese.

Methods: The present study comprised the translation, synthesis of translations, backtranslation, consolidation by a committee of experts, and test of the final version of the CHOP INTEND in 13 patients with SMA type I. We also assessed the content validity and reliability of the translated version.

Results: The scale was translated considering semantic, structural, idiomatic, and cultural aspects. All agreement rates were > 0.8, the overall content validity index of the instrument was 0.98, and inter-rater reliability using the intraclass correlation coefficient was 0.998.

Conclusion: The Brazilian version of the CHOP INTEND met semantic and technical equivalence criteria with the original version and was valid and reliable for patients with SMA type I.

Antecedentes: A atrofia muscular espinhal (AME) é uma doença genética rara que provoca fraqueza muscular progressiva com impacto sobre a motricidade dos pacientes. A AME tipo I é considerada o tipo mais grave e acomete lactentes antes dos 6 meses de idade. As escalas disponíveis para avaliação das aquisições motoras mostram limitações para uso com crianças pequenas com doenças neuromusculares e fraqueza importante.

Objetivo: Realizar a tradução, adaptação transcultural e validação para a língua portuguesa do Brasil da Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND, na sigla em inglês). MéTODOS: O presente estudo seguiu as etapas de tradução, síntese das traduções, retrotradução, consolidação por comitê de especialistas e teste com 13 pacientes com AME tipo 1. Foi avaliada a validade de conteúdo e a confiabilidade do instrumento.

Resultados: A escala foi traduzida considerando os aspectos semânticos, estruturais, idiomáticos e culturais. Todas as taxas de concordância foram > 0,8. O índice de validade de conteúdo geral do instrumento foi de 0,98. A confiabilidade interavaliadores analisada através do coeficiente de correlação intraclasse (ICC, na sigla em inglês) demonstrou um valor de ICC = 0,998. CONCLUSãO: A versão da CHOP INTEND em português atende aos critérios de equivalência semântica e técnica em relação à versão original e apresenta validade de conteúdo e confiabilidade para seu uso na população de pacientes com AME tipo I.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Stages of the transcultural adaptation of the CHOP INTEND to Brazilian Portuguese. Abbreviations: OV, original version; PTV1 and PTV2, Portuguese translated version; STV, synthesis of the translated versions; BTV1 and BTV2, backtranslation to English; PFV, prefinal version; TV, test version; FV, final version.

References

    1. Mercuri E. Spinal muscular atrophy: from rags to riches. Neuromuscul Disord. 2021;31(10):998–1003. doi: 10.1016/j.nmd.2021.08.009. - DOI - PubMed
    1. Farrar M A, Park S B, Vucic S et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017;81(03):355–368. doi: 10.1002/ana.24864. - DOI - PMC - PubMed
    1. Mercuri E, Lucibello S, Perulli M et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis. 2020;15(01):84. doi: 10.1186/s13023-020-01356-1. - DOI - PMC - PubMed
    1. Farrar M A, Kiernan M C. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015;12(02):290–302. doi: 10.1007/s13311-014-0314-x. - DOI - PMC - PubMed
    1. Schorling D C, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy - new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(01):1–13. doi: 10.3233/JND-190424. - DOI - PMC - PubMed

LinkOut - more resources